ArticleCureus2025
Codeine as a Potential Drug Against Motor Symptoms in Parkinson's Disease: Report of Two Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although many drugs for Parkinson's disease (PD) with different modes of action are employed in clinical settings, the wearing-off phenomenon occurs frequently in the advanced stages of the disease; thus, more therapeutic options are required. Our clinical observations have found that the oral administration of codeine phosphate ameliorated wearing-off in two cases of PD. Case 1 was a woman in her 60s. One day, she had a common cold and took an antitussive, expectorant drug, Aneton, an over-the-counter medicine. After taking it, not only were her common cold symptoms ameliorated but her akinesia also improved. Among the ingredients of Aneton, codeine phosphate proved to be effective for her akinesia. Case 2 was a man in his 50s with PD accompanied by severe, intermittent pain. Codeine phosphate prescribed for his pain improved both his pain and bradykinesia. The oral administration of codeine phosphate ameliorated akinesia/bradykinesia in both cases of PD. This suggests the possible efficacy of codeine phosphate against motor symptoms in PD. In the future, a well-designed multicenter trial is needed to assess the use of codeine phosphate for PD patients, particularly to evaluate its efficacy for motor symptoms, its adverse effects, and its long-term prognosis in patients with PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.